Publications

hydroxychloroquine use against sars-cov-2 infection in non-human primates.	coronavirus disease 2019 (covid-19) has rapidly become a global pandemic and no antiviral drug or vaccine is yet available for the treatment of this disease1-3. several clinical studies are ongoing to evaluate the efficacy of repurposed drugs that have demonstrated antiviral efficacy in vitro. among these candidates, hydroxychloroquine (hcq) has been given to thousands of individuals infected with severe acute respiratory syndrome coronavirus 2 (sars-cov-2)-the virus that causes covid-19-worldwi ...	2020	32698191
chloroquine does not inhibit infection of human lung cells with sars-cov-2.	the coronavirus disease 2019 (covid-19) pandemic, which is caused by severe acute respiratory syndrome coronavirus 2 (sars-cov-2), has been associated with more than 780,000 deaths worldwide (as of 20 august 2020). to develop antiviral interventions quickly, drugs used for the treatment of unrelated diseases are currently being repurposed to treat covid-19. chloroquine is an anti-malaria drug that is used for the treatment of covid-19 as it inhibits the spread of sars-cov-2 in the african green ...	2020	32698190
small particle aerosol exposure of african green monkeys to mers-cov as a model for highly pathogenic coronavirus infection.	emerging coronaviruses are a global public health threat because of the potential for person-to-person transmission and high mortality rates. middle east respiratory syndrome coronavirus (mers-cov) emerged in 2012, causing lethal respiratory disease in »35% of cases. primate models of coronavirus disease are needed to support development of therapeutics, but few models exist that recapitulate severe disease. for initial development of a mers-cov primate model, 12 african green monkeys were expos ...	2020	32744989
intranasal exposure of african green monkeys to sars-cov-2 results in acute phase pneumonia with shedding and lung injury still present in the early convalescence phase.	we recently reported the development of the first african green monkey (agm) model for covid-19 based on a combined liquid intranasal (i.n.) and intratracheal (i.t.) exposure to severe acute respiratory syndrome coronavirus 2 (sars-cov-2). here, we followed up on this work by assessing an i.n. particle only route of exposure using the lma mucosal atomization device (mad). six agms were infected with sars-cov-2; three animals were euthanized near the peak stage of virus replication (day 5) and th ...	2020	32811514
intranasal exposure of african green monkeys to sars-cov-2 results in acute phase pneumonia with shedding and lung injury still present in the early convalescence phase.	we recently reported the development of the first african green monkey (agm) model for covid-19 based on a combined liquid intranasal (i.n.) and intratracheal (i.t.) exposure to severe acute respiratory syndrome coronavirus 2 (sars-cov-2). here, we followed up on this work by assessing an i.n. particle only route of exposure using the lma mucosal atomization device (mad). six agms were infected with sars-cov-2; three animals were euthanized near the peak stage of virus replication (day 5) and th ...	2020	32818211
establishment of an african green monkey model for covid-19.	severe acute respiratory syndrome coronavirus 2 (sars-cov-2) is responsible for an unprecedented global pandemic of covid-19. animal models are urgently needed to study the pathogenesis of covid-19 and to screen candidate vaccines and treatments. nonhuman primates (nhp) are considered the gold standard model for many infectious pathogens as they usually best reflect the human condition. here, we show that african green monkeys support a high level of sars-cov-2 replication and develop pronounced ...	2020	32511377
development of a coronavirus disease 2019 nonhuman primate model using airborne exposure.	airborne transmission is predicted to be a prevalent route of human exposure with sars-cov-2. aside from african green monkeys, nonhuman primate models that replicate airborne transmission of sars-cov-2 have not been investigated. a comparative evaluation of covid-19 in african green monkeys, rhesus macaques, and cynomolgus macaques following airborne exposure to sars-cov-2 was performed to determine critical disease parameters associated with disease progression, and establish correlations betw ...	2021	33529233
use of convalescent serum reduces severity of covid-19 in nonhuman primates.	passive transfer of convalescent plasma or serum is a time-honored strategy for treating infectious diseases. human convalescent plasma containing antibodies against severe acute respiratory syndrome coronavirus 2 (sars-cov-2) is currently being used to treat patients with coronavirus disease 2019 where clinical efficacy trials are ongoing. here, we assess therapeutic passive transfer in groups of sars-cov-2-infected african green monkeys with convalescent sera containing either high or low anti ...	2021	33662255
intra-host sars-cov-2 evolution in the gut of mucosally-infected chlorocebus aethiops (african green monkeys).	in recent months, several sars-cov-2 variants have emerged that enhance transmissibility and escape host humoral immunity. hence, the tracking of viral evolutionary trajectories is clearly of great importance. little is known about sars-cov-2 evolution in nonhuman primate models used to test vaccines and therapies and to model human disease. viral rna was sequenced from rectal swabs from chlorocebus aethiops (african green monkeys) after experimental respiratory sars-cov-2 infection. two distinc ...	2022	35062281